Knockdown of ARHGAP30 inhibits ovarian cancer cell proliferation, migration, and invasiveness by suppressing the PI3K/AKT/mTOR signaling pathway

The mortality and morbidity rates of ovarian cancer (OC) are high, but the underlying mechanisms of OC have not been characterized. In this study, we determined the role of Rho GTPase Activating Protein 30 (ARHGAP30) in OC progression. We measured ARHGAP30 abundance in OC tissue samples and cells using immunohistochemistry (IHC) and RT-qPCR. EdU, transwell, and annexin V/PI apoptosis assays were used to evaluate proliferation, invasiveness, and apoptosis of OC cells, respectively. The results showed that ARHGAP30 was overexpressed in OC tissue samples and cells. Inhibition of ARHGAP30 suppressed growth and metastasis of OC cells, and enhanced apoptosis. Knockdown of ARHGAP30 in OC cells significantly inhibited the PI3K/AKT/mTOR pathway. Treatment with the PI3K/AKT/mTOR pathway inhibitor buparlisib simulated the effects of ARHGAP30 knockdown on growth, invasiveness, and apoptosis of OC cells. Following buparlisib treatment, the expression levels of p-PI3K, p-AKT, and p-mTOR were significantly decreased. Furthermore, buparlisib inhibited the effects of ARHGAP30 upregulation on OC cell growth and invasiveness. In conclusion, ARHGAP30 regulated the PI3K/AKT/mTOR pathway to promote progression of OC.

[1]  caixia li,et al.  Repressing IRS1/2 by NT157 inhibits the malignant behaviors of ovarian cancer through inactivating PI3K/AKT/mTOR pathway and inducing autophagy , 2023, The Kaohsiung journal of medical sciences.

[2]  Jing Wang,et al.  SRC-3/TRAF4 facilitates ovarian cancer development by activating the PI3K/AKT signaling pathway , 2023, Medical Oncology.

[3]  Zhi-dong Hu,et al.  Diagnostic performance of CA125, HE4, ROMA, and CPH‐I in identifying primary ovarian cancer , 2023, The journal of obstetrics and gynaecology research.

[4]  P. Tan,et al.  The scaffold RhoGAP protein ARHGAP8/BPGAP1 synchronizes Rac and Rho signaling to facilitate cell migration , 2023, Molecular biology of the cell.

[5]  Kongming Wu,et al.  Increased expression of ECT2 predicts the poor prognosis of breast cancer patients , 2022, Experimental Hematology & Oncology.

[6]  L. Xia,et al.  RHO GTPase family in hepatocellular carcinoma , 2022, Experimental Hematology & Oncology.

[7]  Juan-Ying Xu,et al.  Long noncoding RNA RFPL1S-202 inhibits ovarian cancer progression by downregulating the IFN/STAT1 signaling. , 2022, Experimental cell research.

[8]  Xin Huang,et al.  Novel Platinum Nanoclusters Activate PI3K/AKT/mTOR Signaling Pathway-Mediated Autophagy for Cisplatin-Resistant Ovarian Cancer Therapy. , 2022, ACS applied materials & interfaces.

[9]  H. Yagi,et al.  Tumor-derived ARHGAP35 mutations enhance the Gα_13-Rho signaling axis in human endometrial cancer , 2022, Cancer Gene Therapy.

[10]  Xiaojing Zhang,et al.  The RAC/ROP GTPase Activator OsRopGEF10 functions in crown root development by regulating cytokinin signaling in rice. , 2022, The Plant cell.

[11]  F. Salsbury,et al.  Compound C Inhibits Ovarian Cancer Progression via PI3K-AKT-mTOR-NFκB Pathway , 2022, Cancers.

[12]  Xiaoqian Zhang,et al.  OCT4 induces EMT and promotes ovarian cancer progression by regulating the PI3K/AKT/mTOR pathway , 2022, Frontiers in Oncology.

[13]  Meng Li,et al.  DDTC Suppresses Ovarian Cancer Development via the PI3K/AKT/mTOR Signaling Pathway , 2022, Disease markers.

[14]  Shufeng Zhou,et al.  CXCR4 knockdown enhances sensitivity of paclitaxel via the PI3K/Akt/mTOR pathway in ovarian carcinoma , 2022, Aging.

[15]  Deyuan Zhang,et al.  DNA methylation of ARHGAP30 is negatively associated with ARHGAP30 expression in lung adenocarcinoma, which reduces tumor immunity and is detrimental to patient survival , 2021, Aging.

[16]  Xiao-Mei Yang,et al.  Overexpression of ARHGAP30 suppresses growth of cervical cancer cells by downregulating ribosome biogenesis , 2021, Cancer science.

[17]  Xiushan Feng,et al.  TCP1 regulates PI3K/AKT/mTOR signaling pathway to promote proliferation of ovarian cancer cells , 2021, Journal of Ovarian Research.

[18]  G. Hong,et al.  Identification of differential DNA methylation alterations of ovarian cancer in peripheral whole blood based on within-sample relative methylation orderings , 2021, Epigenetics.

[19]  Xiaolei Liang,et al.  METTL3-mediated maturation of miR-126-5p promotes ovarian cancer progression via PTEN-mediated PI3K/Akt/mTOR pathway , 2020, Cancer Gene Therapy.

[20]  Yongping Zhou,et al.  Upregulation of ARHGAP30 attenuates pancreatic cancer progression by inactivating the β-catenin pathway , 2020, Cancer Cell International.

[21]  Yongping Zhou,et al.  Upregulation of ARHGAP30 attenuates pancreatic cancer progression by inactivating the β-catenin pathway , 2020, Cancer Cell International.

[22]  Jinhua Zhang,et al.  mTOR Signaling in Cancer and mTOR Inhibitors in Solid Tumor Targeting Therapy , 2019, International journal of molecular sciences.

[23]  Xiaoliang Mao,et al.  ARHGAP30 suppressed lung cancer cell proliferation, migration, and invasion through inhibition of the Wnt/β-catenin signaling pathway , 2018, OncoTargets and therapy.

[24]  Cheng Li,et al.  GEPIA: a web server for cancer and normal gene expression profiling and interactive analyses , 2017, Nucleic Acids Res..

[25]  N. Lu,et al.  A new role for the PI3K/Akt signaling pathway in the epithelial-mesenchymal transition , 2015, Cell adhesion & migration.

[26]  Jie Xu,et al.  ArhGAP30 promotes p53 acetylation and function in colorectal cancer , 2014, Nature Communications.

[27]  K. Shen,et al.  PI3K/AKT/mTOR signaling pathway as a therapeutic target for ovarian cancer , 2014, Archives of Gynecology and Obstetrics.

[28]  P. Aspenström,et al.  ARHGAP30 is a Wrch-1-interacting protein involved in actin dynamics and cell adhesion. , 2011, Biochemical and biophysical research communications.

[29]  Christian von Mering,et al.  STRING: known and predicted protein–protein associations, integrated and transferred across organisms , 2004, Nucleic Acids Res..